Novel Arcyriaflavin-A Derivatives as PIM Kinase Inhibitors for Treating Cancer
Author:
Affiliation:
1. Department of Chemistry, Conju-Probe, San Diego, California, USA
2. Bharath University, Chennai, Tamil Nadu, 600126, India
Abstract
Publisher
Bentham Science Publishers Ltd.
Subject
Cancer Research,Pharmacology,Molecular Medicine
Reference21 articles.
1. Walhekar V.; Bagul C.; Kumar D.; Muthal A.; Achaiah G.; Kulkarni R.; Topical advances in PIM kinases and their inhibitors: Medicinal chemistry perspectives. Biochim Biophys Acta Rev Cancer 2022,1877(3),188725
2. Rathi A.; Kumar D.; Hasan G.M.; Haque M.M.; Hassan M.I.; Therapeutic targeting of PIM KINASE signaling in cancer therapy: Structural and clinical prospects. Biochim Biophys Acta, Gen Subj 2021,1865(11),129995
3. Panchal N.K.; Sabina E.P.; A serine/threonine protein PIM kinase as a biomarker of cancer and a target for anti-tumor therapy. Life Sci 2020,255,117866
4. Asati V.; Mahapatra D.K.; Bharti S.K.; PIM kinase inhibitors: Structural and pharmacological perspectives. Eur J Med Chem 2019,172,95-108
5. Le B.T.; Kumarasiri M.; Adams J.R.J.; Yu M.; Milne R.; Sykes M.J.; Wang S.; Targeting Pim kinases for cancer treatment: Opportunities and challenges. Future Med Chem 2015,7(1),35-53
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3